Why Moderna Stock Plunged Today

Moderna (NASDAQ: MRNA) shares fell 9% on Tuesday as biotechnology tested whether its coronavirus vaccine would be effective against a highly contagious new strain of the virus. Investors and the world cheered when a Phase 3 clinical trial showed Moderna's vaccine candidate, mRNA-1273, is 94% effective against COVID-19 and 100% effective against severe forms of the disease. Moderna's share price nearly doubled after the drug maker released data from an interim analysis of the clinical trial in mid-November.

You should check here to buy the best price guaranteed products.

Last News

CDC recommends Pfizer booster shots for certain Americans

Meet T Wierson: Elvira Shares First Photo of Girlfriend of 19 Years

'Miracle house' spared from La Palma lava

Georgia secretary of state slams Trump ahead of rally: 'He knows in his heart' he lost

30 celebrities you probably forgot played bad guys on 'Law and Order: SVU'

Hilarie Burton Reveals Touching Tattoo She Got to Honor Willie Garson Before His Death